- Fee assured
- Awaiting verification
- Inflammatory bowel disease
Dr Creed qualified and spent his early training years in London and completed his specialist training in Bristol and the Southwest. During this time he developed a specialist interest in the treatment of inflammatory bowel diseases.
He was awarded an MD from the University of London for work developing a new treatment for ulcerative colitis. He continues to be actively involved in clinical research as Director of the Joint Clinical Research Unit, Divisional Lead for Research at the Bristol Royal Infirmary and co-chair of the South West Inflammatory Bowel Disease Network.
Dr Creed has a strong interest in endoscopy, particularly colonoscopy. He is a national colonoscopy examiner for the NHS Bowel Cancer Screening Programme, and has expertise in the management of colonic polyps.
He is a member of the regional nutrition service at the BRI and has extensive experience of managing complex nutrition and intestinal failure.
Areas of interest
Gastroscopy; colonoscopy; flexible sigmoidoscopy; inflammatory bowel disease; bowel cancer screening; change in bowel habit; nutrition
Current NHS consultant posts held
Consultant Gastroenterologist, Bristol Royal Infirmary
•Principal investigator for multiple clinical studies
•Active research programme in inflammatory bowel disease in collaboration with University of Bristol and the Biomedical Research Unit in Nutrition
•Active research programme in the prevention of colonic polyps in collaboration with the University of Bristol
•Multiple publications in the field of inflammatory Bowel Disease
Dr Creed enjoys surfing, running, and spending time with his family.
Clinical features and HLA association of 5-Aminosalicylate (5-ASA) induced nephrotoxicity in inflammatory bowel disease.
J Crohns Colitis. 2015 Nov 29. pii: jjv219. [Epub ahead of print]
HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants
Nat Genet. 2014 Oct;46(10)
A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease
Aliment Pharmacol Ther. 2013 Jul;38(1):52-61
Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis.
Gastroenterology. 2012 Aug;143(2):356-64.
Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials?
Inflamm Bowel Dis. 2012 Nov;18(11):2056-62.
Increased serum free tryptophan in patients with diarrhoea-predominant irritable bowel syndrome.
Nutr Res. 2010 Oct;30(10):678-88.
Clinical experience of methotrexate in Crohn's disease: response, safety and monitoring of treatment.
Postgrad Med J. 2010 Apr;86(1014):208-11.
The effects of cytokines on suppression of lymphocyte proliferation by dexamethasone.
J Immunol. 2009 Jul 1;183(1):164-71.
Basiliximab and infliximab for the treatment of steroid-refractory Crohn's disease.
Am J Gastroenterol. 2008 Oct;103(10):2665.
- MB BS University of London 1994
- BSc (Hons.) Pharmaclogy University of London 1991
- MD University of London 1996
Reference number 4106340
Information for healthcare professionals (Bupa patients only, last 12 months)
IV sedation administered by operator - (5-50)
Diagnostic oesophago-gastro-duodenoscopy (OGD) includes forceps biopsy, biopsy urease test and dye spray - (5-50)
Diagnostic colonoscopy, includes forceps biopsy of colon and ileum - (5-50)
Diagnostic flexible sigmoidoscopy (including forceps biopsy and proctoscopy) - (1-5)
Diagnostic oesophago-gastro-duodenoscopy (OGD) and immediate colonoscopy includes forceps biopsies, biopsy test and dye spray (as sole procedure) - (1-5)